Cryoport Exceeds FY25 Revenue Guidance, Reports Strong CGT Growth, and Issues FY26 Outlook

summarizeSummary

Cryoport, Inc. announced Q4 and FY25 financial results, exceeding full-year revenue guidance with strong growth in Life Sciences Services and commercial cell and gene therapy support, alongside improved adjusted EBITDA and a positive FY26 revenue outlook.

check_boxKey Events

• Exceeded FY25 Revenue Guidance

  Cryoport reported full-year 2025 revenue of $176.2 million, surpassing the high end of its previous guidance and representing a 12% year-over-year increase.

• Strong Growth in Life Sciences Services

  Life Sciences Services revenue grew 18% year-over-year in FY25 to $96.5 million, with commercial cell and gene therapy revenue increasing 29% to $33.4 million.

• Issued FY26 Revenue Guidance

  The company provided full-year 2026 revenue guidance in the range of $190.0 million to $194.0 million, indicating an expected 8%-10% year-over-year growth.

• Improved Adjusted EBITDA and Strong Cash Position

  Adjusted EBITDA from continuing operations improved to a negative $5.8 million for FY25, compared to a negative $17.8 million in FY24. The company held $411.2 million in cash, cash equivalents, and short-term investments as of December 31, 2025.

auto_awesomeAnalysis

Cryoport, Inc. reported strong financial results for fiscal year 2025, surpassing its own revenue guidance and demonstrating significant growth in its core Life Sciences Services segment, particularly in commercial cell and gene therapy (CGT) support. The company's strategic divestiture of CRYOPDP contributed substantially to the reported net income for the year, while adjusted EBITDA from continuing operations showed a marked improvement, indicating progress towards profitability. The provided full-year 2026 revenue guidance suggests continued growth, reinforcing investor confidence in the company's market position and operational execution within the rapidly expanding life sciences supply chain sector.